{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Abrahamson EE"],"funding":["NIA NIH HHS","NHLBI NIH HHS"],"pagination":["169-187"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10199962"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(2)"],"pubmed_abstract":["<h4>Background</h4>[<sup>18</sup>F]flutemetamol is a PET radioligand used to image brain amyloid, but its detection of myocardial amyloid is not well-characterized. This histological study characterized binding of fluorescently labeled flutemetamol (cyano-flutemetamol) to amyloid deposits in myocardium.<h4>Methods</h4>Myocardial tissue was obtained post-mortem from 29 subjects with cardiac amyloidosis including transthyretin wild-type (ATTRwt), hereditary/variant transthyretin (ATTRv) and immunoglobulin light-chain (AL) types, and from 10 cardiac amyloid-free controls. Most subjects had antemortem electrocardiography, echocardiography, SPECT and cardiac MRI. Cyano-flutemetamol labeling patterns and integrated density values were evaluated relative to fluorescent derivatives of Congo red (X-34) and Pittsburgh compound-B (cyano-PiB).<h4>Results</h4>Cyano-flutemetamol labeling was not detectable in control subjects. In subjects with cardiac amyloidosis, cyano-flutemetamol labeling matched X-34- and cyano-PiB-labeled, and transthyretin- or lambda light chain-immunoreactive, amyloid deposits and was prevented by formic acid pre-treatment of myocardial sections. Cyano-flutemetamol mean fluorescence intensity, when adjusted for X-34 signal, was higher in the ATTRwt than the AL group. Cyano-flutemetamol integrated density correlated strongly with echocardiography measures of ventricular septal thickness and posterior wall thickness, and with heart mass.<h4>Conclusion</h4>The high selectivity of cyano-flutemetamol binding to myocardial amyloid supports the diagnostic utility of [<sup>18</sup>F]flutemetamol PET imaging in patients with ATTR and AL types of cardiac amyloidosis."],"journal":["Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis"],"pubmed_title":["The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis."],"pmcid":["PMC10199962"],"funding_grant_id":["R01 HL130563","K24 HL157648","P01 AG025204","R01 HL150342","P01 AG014449","R01 AG052528","K24 HL152008"],"pubmed_authors":["Abrahamson EE","Ikonomovic MD","Padera RF","Dorbala S","Davies J","Farrar G","Villemagne VL"],"additional_accession":[]},"is_claimable":false,"name":"The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis.","description":"<h4>Background</h4>[<sup>18</sup>F]flutemetamol is a PET radioligand used to image brain amyloid, but its detection of myocardial amyloid is not well-characterized. This histological study characterized binding of fluorescently labeled flutemetamol (cyano-flutemetamol) to amyloid deposits in myocardium.<h4>Methods</h4>Myocardial tissue was obtained post-mortem from 29 subjects with cardiac amyloidosis including transthyretin wild-type (ATTRwt), hereditary/variant transthyretin (ATTRv) and immunoglobulin light-chain (AL) types, and from 10 cardiac amyloid-free controls. Most subjects had antemortem electrocardiography, echocardiography, SPECT and cardiac MRI. Cyano-flutemetamol labeling patterns and integrated density values were evaluated relative to fluorescent derivatives of Congo red (X-34) and Pittsburgh compound-B (cyano-PiB).<h4>Results</h4>Cyano-flutemetamol labeling was not detectable in control subjects. In subjects with cardiac amyloidosis, cyano-flutemetamol labeling matched X-34- and cyano-PiB-labeled, and transthyretin- or lambda light chain-immunoreactive, amyloid deposits and was prevented by formic acid pre-treatment of myocardial sections. Cyano-flutemetamol mean fluorescence intensity, when adjusted for X-34 signal, was higher in the ATTRwt than the AL group. Cyano-flutemetamol integrated density correlated strongly with echocardiography measures of ventricular septal thickness and posterior wall thickness, and with heart mass.<h4>Conclusion</h4>The high selectivity of cyano-flutemetamol binding to myocardial amyloid supports the diagnostic utility of [<sup>18</sup>F]flutemetamol PET imaging in patients with ATTR and AL types of cardiac amyloidosis.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-03-17T16:11:23.201Z","creation":"2025-08-18T09:53:06.125Z"},"accession":"S-EPMC10199962","cross_references":{"pubmed":["36411500"],"doi":["10.1080/13506129.2022.2141623"]}}